152 related articles for article (PubMed ID: 17663538)
1. Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.
Morningstar ML; Roth T; Farnsworth DW; Smith MK; Watson K; Buckheit RW; Das K; Zhang W; Arnold E; Julias JG; Hughes SH; Michejda CJ
J Med Chem; 2007 Aug; 50(17):4003-15. PubMed ID: 17663538
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles.
Roth T; Morningstar ML; Boyer PL; Hughes SH; Buckheit RW; Michejda CJ
J Med Chem; 1997 Dec; 40(26):4199-207. PubMed ID: 9435891
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling calculations of HIV-1 reverse transcriptase nonnucleoside inhibitors: correlation of binding energy with biological activity for novel 2-aryl-substituted benzimidazole analogues.
Kroeger Smith MB; Hose BM; Hawkins A; Lipchock J; Farnsworth DW; Rizzo RC; Tirado-Rives J; Arnold E; Zhang W; Hughes SH; Jorgensen WL; Michejda CJ; Smith RH
J Med Chem; 2003 May; 46(10):1940-7. PubMed ID: 12723956
[TBL] [Abstract][Full Text] [Related]
4. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
Monforte AM; Ferro S; De Luca L; Lo Surdo G; Morreale F; Pannecouque C; Balzarini J; Chimirri A
Bioorg Med Chem; 2014 Feb; 22(4):1459-67. PubMed ID: 24457088
[TBL] [Abstract][Full Text] [Related]
6. Structural optimization of N
Monforte AM; De Luca L; Buemi MR; Agharbaoui FE; Pannecouque C; Ferro S
Bioorg Med Chem; 2018 Feb; 26(3):661-674. PubMed ID: 29291935
[TBL] [Abstract][Full Text] [Related]
7. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
[TBL] [Abstract][Full Text] [Related]
8. New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
Le Van K; Cauvin C; de Walque S; Georges B; Boland S; Martinelli V; Demonté D; Durant F; Hevesi L; Van Lint C
J Med Chem; 2009 Jun; 52(12):3636-43. PubMed ID: 19469474
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Mai A; Sbardella G; Artico M; Ragno R; Massa S; Novellino E; Greco G; Lavecchia A; Musiu C; La Colla M; Murgioni C; La Colla P; Loddo R
J Med Chem; 2001 Aug; 44(16):2544-54. PubMed ID: 11472208
[TBL] [Abstract][Full Text] [Related]
10. The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
Xu G; Micklatcher M; Silvestri MA; Hartman TL; Burrier J; Osterling MC; Wargo H; Turpin JA; Buckheit RW; Cushman M
J Med Chem; 2001 Nov; 44(24):4092-113. PubMed ID: 11708913
[TBL] [Abstract][Full Text] [Related]
11. Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT.
Barreca ML; Rao A; De Luca L; Zappalà M; Monforte AM; Maga G; Pannecouque C; Balzarini J; De Clercq E; Chimirri A; Monforte P
J Med Chem; 2005 May; 48(9):3433-7. PubMed ID: 15857150
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase.
Sudbeck EA; Mao C; Vig R; Venkatachalam TK; Tuel-Ahlgren L; Uckun FM
Antimicrob Agents Chemother; 1998 Dec; 42(12):3225-33. PubMed ID: 9835518
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.
Johnson BC; Pauly GT; Rai G; Patel D; Bauman JD; Baker HL; Das K; Schneider JP; Maloney DJ; Arnold E; Thomas CJ; Hughes SH
Retrovirology; 2012 Dec; 9():99. PubMed ID: 23217210
[TBL] [Abstract][Full Text] [Related]
14. Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives.
Genin MJ; Biles C; Keiser BJ; Poppe SM; Swaney SM; Tarpley WG; Yagi Y; Romero DL
J Med Chem; 2000 Mar; 43(5):1034-40. PubMed ID: 10715167
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.
Ranise A; Spallarossa A; Schenone S; Bruno O; Bondavalli F; Vargiu L; Marceddu T; Mura M; La Colla P; Pani A
J Med Chem; 2003 Feb; 46(5):768-81. PubMed ID: 12593657
[TBL] [Abstract][Full Text] [Related]
16. Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains.
Sang Y; Han S; Han S; Pannecouque C; De Clercq E; Zhuang C; Chen F
Bioorg Chem; 2019 Aug; 89():102974. PubMed ID: 31102693
[TBL] [Abstract][Full Text] [Related]
17. [Design, synthesis and biologic evaluation of diarylbenzimidazole derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors].
Qin BJ; Zhou T; Lu H; Jiang SB; Xie L
Yao Xue Xue Bao; 2009 Nov; 44(11):1233-43. PubMed ID: 21355324
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 reverse transcriptase variants: molecular modeling of Y181C, V106A, L100I, and K103N mutations with nonnucleoside inhibitors using Monte Carlo simulations in combination with a linear response method.
Smith MB; Ruby S; Horouzhenko S; Buckingham B; Richardson J; Puleri I; Potts E; Jorgensen WL; Arnold E; Zhang W; Hughes SH; Michejda CJ; Smith RH
Drug Des Discov; 2003; 18(4):151-63. PubMed ID: 15553926
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
Ranise A; Spallarossa A; Cesarini S; Bondavalli F; Schenone S; Bruno O; Menozzi G; Fossa P; Mosti L; La Colla M; Sanna G; Murreddu M; Collu G; Busonera B; Marongiu ME; Pani A; La Colla P; Loddo R
J Med Chem; 2005 Jun; 48(11):3858-73. PubMed ID: 15916438
[TBL] [Abstract][Full Text] [Related]
20. N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
Novikov MS; Valuev-Elliston VT; Babkov DA; Paramonova MP; Ivanov AV; Gavryushov SA; Khandazhinskaya AL; Kochetkov SN; Pannecouque C; Andrei G; Snoeck R; Balzarini J; Seley-Radtke KL
Bioorg Med Chem; 2013 Mar; 21(5):1150-8. PubMed ID: 23357038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
